Docetaxel is a semi-synthetic, second-generation taxane derived from the European yew tree (Taxus baccata). It is a potent antineoplastic agent belonging to the taxane class, widely used in the Indian oncology setting for the treatment of various solid tumors. The 120mg single-dose vial is a standard presentation for adult dosing, typically administered as an intravenous infusion after dilution. It acts primarily by promoting microtubule assembly and stabilization, inhibiting mitosis and leading to cell death in rapidly dividing cancer cells.
Adult: Usual dose: 75-100 mg/m² body surface area, administered as a one-hour intravenous infusion every 3 weeks. The 120mg vial is used as part of the calculated dose. Dose adjustments are based on toxicity (especially neutropenia).
Note: 1. MUST be diluted prior to infusion. The 120mg vial concentrate is diluted in 250 mL of either 0.9% Sodium Chloride or 5% Dextrose injection. 2. Final concentration should be between 0.3 to 0.9 mg/mL. 3. Administer as a one-hour IV infusion using a non-PVC container and tubing (use polyethylene-lined sets). 4. Strict aseptic technique is required. 5. Premedication with corticosteroids (e.g., oral dexamethasone 8 mg twice daily for 3 days, starting one day before docetaxel) is mandatory.
Docetaxel binds reversibly to the beta-tubulin subunit of microtubules with high affinity. This binding promotes the assembly of stable, non-functional microtubule bundles and inhibits their depolymerization, a process essential for normal cellular mitosis (M phase of the cell cycle). This leads to a blockade of cells in the metaphase/anaphase transition, inhibiting cell division and ultimately inducing apoptotic cell death.
Pregnancy: Category D: Positive evidence of human fetal risk. Can cause fetal harm. Contraindicated. Women of childbearing potential must use effective contraception during and for some months after therapy.
Driving: May cause fatigue, dizziness, or neuropathy. Patients should be cautioned about operating machinery or driving if they experience these effects.
| Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | May significantly increase docetaxel plasma concentrations, leading to increased risk of severe toxicity (e.g., neutropenia). | Major |
| Strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine, St. John's Wort) | May significantly decrease docetaxel plasma concentrations, potentially reducing its efficacy. | Major |
| Other Myelosuppressive Agents (e.g., other chemotherapies like Gemcitabine, Doxorubicin) | Additive risk of severe bone marrow suppression (neutropenia, thrombocytopenia, anemia). | Major |
| Live Vaccines (e.g., MMR, Varicella, Yellow Fever) | Increased risk of vaccine-induced infection due to immunosuppression. | Major |